Objectives: In the first days after cardiac arrest, accurate prognostication is challenging. Serum biomarkers are a potentially attractive adjunct for prognostication and risk stratification. Our primary objective in this exploratory study was to identify novel early serum biomarkers that predict survival after cardiac arrest earlier than currently possible. Design: Prospective, observational study. Setting: A single academic medical center. Subjects: Adult subjects who sustained cardiac arrest with return of spontaneous circulation. Intervention: None.
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For information regarding this article, E-mail: rittjc@upmc.edu Serum Neutrophil Gelatinase-Associated Lipocalin Predicts Survival After Resuscitation From Cardiac Arrest 4). In the first 72 hours after ROSC, no known clinical finding or diagnostic test has adequate specificity for poor outcome or anticipated clinical course to inform clinical care or accurate neurologic prognostication (5) (6) (7) . Thus, it is difficult to prospectively identify and intervene upon high-risk patients before deterioration, and in most cases, at least 3 days of critical care are necessary before accurate prognostication is possible, creating a burden to families and the healthcare system.
Serum biomarkers are a potentially attractive adjunct for prognostication and risk stratification. The best-described serum biomarkers after CA are neuron-specific enolase (NSE) and S100B protein, which are released into the blood following anoxic brain injury and may reflect the severity of injury (8, 9) . Unfortunately, NSE levels peak between 48 and 72 hours after ROSC and so do not predict outcomes early after ROSC, and recent consensus guidelines have concluded that S100B lacks sufficient precision and discrimination to be clinically useful (8, 9) .
Our primary objective in this exploratory study was to identify novel early serum biomarkers that predict survival after CA earlier than currently possible. The postarrest syndrome is characterized by multiple organ dysfunction secondary to global ischemia-reperfusion injury and a systemic inflammatory response (10) (11) (12) . As such, rather than testing markers of brain injury as have been previously evaluated, we selected candidate biomarkers from molecular pathways related to systemic inflammation (T-cell activation, leukocyte adhesion and activation, and toll-like receptor-mediated innate immunity) that might reflect the extent of total body injury.
MATERIALS AND METHODS

Study Design
We performed a prospective, observational study enrolling consecutive subjects at a single academic medical center. The University of Pittsburgh Institutional Review Board approved all aspects of this study, and either the subject or a legally authorized proxy provided written informed consent before enrollment.
Patients and Setting
The University of Pittsburgh Medical Center Presbyterian Hospital is a 795-bed tertiary-care referral center. Our Post-Cardiac Arrest Service provides standardized care to over 250 patients admitted after CA annually. During the study period, this included routine use of therapeutic hypothermia for comatose patients, defined as not following commands within 6 hours of ROSC, regardless of initial arrest rhythm or arrest location (13) . Our standard practice was to induce hypothermia as rapidly as possible with IV boluses of 4°C crystalloid, application of ice to the neck, axillae and groins, and surface or endovascular cooling systems, targeting a core temperature of 33°C. We maintained hypothermia for 24 hours and then rewarmed patients to normothermia over 16 hours at a rate of 0.25°C/hr to a goal temperature of 37°C that we maintained until 5 days after ROSC or awakening. We included subjects in this study who suffered an in-hospital CA (IHCA) or out-of-hospital CA (OHCA) with ROSC and were admitted to the emergency department (ED) or ICU between January 1, 2007, and December 31, 2009 . We excluded subjects who were younger than 18 years old, presented greater than 6 hours after ROSC or had withdrawal life-sustaining therapy within 6 hours of presentation, pregnant, prisoner, or arrested secondary to a surgical or traumatic etiology. We defined "CA" as a subject having received chest compressions or defibrillation from a health care provider and considered arrests in the ED to be OHCA.
Measurements
We obtained blood samples from each subject at enrollment, 6, 12, 24, 48, and 72 hours after ROSC. We collected samples in 2.7 mL of plastic tubes with 3.2% buffered sodium citrate additive and 10 mL of plastic serum tubes without additives (Becton, Dickinson and Company, Franklin Lakes, NJ) that we rested for 20 minutes before centrifugation at 3000 rpm for 10 minutes. We removed the supernatant and stored it in Eppendorf tubes at -80°C until analysis. We measured the serum levels of novel biomarkers in the postarrest population, including neutrophil gelatinase-associated lipocalin (NGAL), highmobility group protein B1 (HMGB), intracellular cell adhesion molecule-1 (ICAM-1), and leptin, as well as previously characterized biomarkers, including NSE and S100B protein. We used Luminex immunofluorescence assays (Millipore, Billerica, MA) and analyzed samples according to manufacturer's instructions (http://www.millipore.com).
We prospectively recorded baseline characteristics, including subject age, sex, presenting arrest rhythm (categorized as shockable [ventricular tachycardia/fibrillation] or nonshockable [pulseless electrical activity, asystole, or unknown]), arrest location (IHCA or OHCA), Sequential Organ Failure Assessment (SOFA) score, use of therapeutic hypothermia, and Pittsburgh Cardiac Arrest Category (PCAC). The PCAC is a clinical prediction tool that stratifies CA survivors by their risk of subsequent death or neurologic deterioration based on clinical characteristics during the first 6 hours after ROSC (14) . This tool divides survivors of CA into four categories that are predictive of survival and functional outcome. Because it could potentially affect biomarker clearance, we recorded each subject's temperature hourly for the first 36 hours and then at 48 and 72 hours. As a measure of ongoing cardiovascular dysfunction and the severity of the post-CA inflammatory syndrome, we recorded cumulative vasopressor index (CVI) hourly for the first 24 hours. The CVI is a method of standardizing vasopressor dosing (15, 16) .
We defined acute kidney injury (AKI) according to the AKI network criteria (17) as a rise in serum creatinine (SCr) of greater than or equal to 0.3 mg/dL within 48 hours of ROSC or greater than or equal to 1.5-fold from baseline, or the need for renal replacement therapy, and treated AKI as a dichotomous outcome. We recorded SCr level at presentation and the peak value within 72 hours (± 12 hours) of ROSC, as well as each subject's prearrest baseline SCr. When a prearrest baseline was not available within the previous 6 months, we treated the lowest SCr after arrest as that subject's baseline. SCr was checked at the discretion of the treating clinician, and measurements were performed by the hospital's clinical laboratory. For patients who were discharged from the hospital less than 5 days after ROSC, we assumed that renal function did not deteriorate after discharge and so if they had not developed AKI before discharge, they were classified as having no AKI.
We recorded each subject's outcomes, including survivalto-hospital discharge, neurologic function at hospital discharge measured using the Pittsburgh Cerebral Performance Category (CPC), development of AKI, and ICU length of stay. Finally, for nonsurvivors, we recorded each subject's mode of death, which we categorized as withdrawal of life-sustaining therapy based on anticipated neurologic prognosis; brain death; withdrawal of life-sustaining therapy based on previous advanced directives or a surrogate's representation of the subject's wishes; or multiple system organ failure, hemodynamic instability, or rearrest without successful resuscitation.
Statistical Methods
Serum biomarker levels were not normally distributed, and no transformation consistently minimized skewness. Therefore, we used nonparametric tests for all analyses. We summarized baseline clinical characteristics and reported medians with interquartile ranges (IQRs). Our primary outcome of interest was survival-to-hospital discharge. To determine whether each biomarker profile differed between those who survived to discharge and those who did not, we compared the level between survivors and nonsurvivors using Wilcoxon signed rank-sum tests at each time point and reported medians, IQRs, and p values for these comparisons. Since the accuracy of early predictions of outcome is of the greatest clinical interest, the remainder of our analyses focused on enrollment biomarker levels. First, we used unadjusted logistic regression to test the association between each baseline clinical characteristic and biomarker level with survival. We quantified the discriminatory power of each biomarker that was associated with survival (27) Baseline Sequential Organ Failure Assessment score 6 (4-6) 9 (7-9) 7 (5-10)
Baseline serum creatinine, mg/dL 1 (0.9-1) 1. at enrollment by generating receiver operating characteristic (ROC) curves and reported area under the curve (AUC) with associated 95% CIs and p values. Next, we sequentially explored the independent association of each enrollment biomarker with after survival adjusting for baseline clinical characteristics associated with survival at a level of p value of less than 0.1. We excluded SOFA score and therapeutic hypothermia from these models, as they are collinear with PCAC. Based on these models, the enrollment NGAL level demonstrated the most favorable performance characteristics; so, we used three additional approaches to further explore its utility. Since biomarker levels could be influenced by the presence of AKI (18, 19) , we forced "development of AKI within 72 hours" as a binary predictor into the adjusted model constructed above. Next, since a combination of multiple biomarkers and clinical characteristics might perform better than a model including only a single biomarker, we used forward selection to determine the most predictive combination of baseline clinical characteristics and biomarkers. We selected a probability of entry and removal of 0.1 and 0.2, respectively, and included all baseline clinical characteristics and enrollment biomarker levels as potential covariates. We evaluated the predictive performance of each of these models by computing c-statistics. Finally, we assessed the contribution of enrollment NGAL to each model by comparing c-statistics and integrated discrimination improvement (IDI) for each adjusted model with and without NGAL. We performed all analyses using Stata Version 13.1 (StataCorp, College Station, TX).
RESULTS baseline Characteristics and Outcomes
A total of 86 subjects were enrolled. Median age was 56 years (IQR, 45-70 yr), and 58% were men ( Table 1) . Most patients 
115
(69%) were enrolled after an OHCA, and multiple organ system dysfunction was common at presentation (median SOFA score, 5 [IQR, 7-10]). AKI was present at presentation in 53 subjects (62%), and a majority of subjects met criteria for AKI within the first 5 hospital days ( Table 2) . Overall, 69 subjects (80%) survived at least 72 hours after ROSC, 39 subjects (45%) survived to hospital discharge, and 7 survivors (18%) were discharged with a CPC of 1-2.
Unadjusted Analysis
In unadjusted analysis, an initial shockable rhythm was asso- Table 3) . The presence of AKI at baseline, within 72 hours and within 5 days of ROSC, was not associated with outcome. Enrollment levels of HMGB, NGAL, and S100B were higher in nonsurvivors than those in survivors (Fig. 1) . The AUC of the ROC curve for enrollment NGAL level was 0.78 (95% CI, 0.66-0.90) and remained similar at all time points ( Fig. 2 and Table 4 ). Enrollment NGAL below 58,000 ng/mL was perfectly specific for survival-to-hospital discharge (Fig. 2) . Conversely, enrollment NGAL above 188,000 ng/mL was 96% specific for nonsurvival. Consistent with previous work (9) , NSE levels in nonsurvivors began to rise after 12-24 hours and were maximally separated at 48 hours, whereas S100B levels began to fall after 12 hours.
Adjusted Analysis
In our adjusted models, the enrollment NGAL level was independently associated with survival, regardless of whether we forced development of AKI into the model ( Table 5 ). When we removed enrollment NGAL from each of these models, the overall model fit and discriminatory power declined ( Table 5 ). Addition of enrollment NGAL to each clinical model resulted in a significant increase in IDI and predictive accuracy ( 
DISCUSSION
The main finding of our study is that the serum NGAL level is strongly predictive of outcome after CA. At enrollment, NGAL performed better than the other candidate biomarkers, including NSE and S100b, which has been better investigated after CA. In addition, addition of enrollment NGAL to clinical models resulted in a significant increase in the discriminatory power of these models. Notably, the association between NGAL and outcome remained stable at all time points up to 72 hours after ROSC. Thus, even in the case of interfacility transfer, where time from arrest to presentation at the final treating hospital may be considerably delayed, the prognostic value of NGAL is preserved. NGAL is expressed in a variety of tissues, including kidney, liver, and lung (20) . Plasma levels may be elevated in a variety of pathologic inflammatory states, including heart failure and malignancy (20) . In AKI, NGAL is secreted both by neutrophils that contribute to tubular injury and directly by tubular epithelial cells themselves (21) . Compared with SCr, NGAL rises earlier and may be a more sensitive marker of AKI; in addition, in risk-adjusted analyses, development of AKI independently predicts mortality (18, 19) . Thus, it is possible that the association between NGAL and outcomes in this cohort is related to underlying, subclinical AKI. Overt AKI detected by the change in SCr was not associated with mortality after CA in a previous study (22) nor did we find an association between AKI and outcome in this cohort. However, SCr is relatively insensitive for AKI, and it is possible that the NGAL is a more sensitive marker for subclinical but important AKI. Alternatively, as a nonspecific inflammatory marker (20) , NGAL may also reflect the overall severity of systemic inflammation in the post-CA syndrome (10) (11) (12) . In this regard, NGAL may be an easily measurable surrogate measure of covariates, such as duration of pulselessness, quality of cardiopulmonary resuscitation (CPR), and total burden of anoxic and ischemia-reperfusion injury, metrics which are at present are unreliably available or difficult to quantify for clinical or research purposes (23) (24) (25) . Both NSE and S100B have been proposed to be specific markers of brain injury and evaluated in the CA population. NSE is an intracellular enzyme involved in glucose metabolism found in not only neurons and neuroendocrine cells but also platelets and erythrocytes (26) . To our knowledge, the largest study that used NSE as a prognostic biomarker after CA was the PROPAC study, which was conducted before the widespread implementation of targeted temperature management (27) . This study suggested that an NSE value above 33 µg/L uniformly predicted poor outcome. However, hypothermia attenuates the rise in NSE levels, which limits the applicability of the PROPAC results to current clinical care. Furthermore, as redemonstrated by our results this present study, NSE rises slowly after CA and is not predictive of outcome in the first days after ROSC, limiting its utility during the first 48-72 hours after ROSC when accurate prognostication is most challenging (28) . S100B is an intracellular calcium-binding protein found in glial cells and may be more specific to brain injury than NSE (26) . Our results are consistent with previous studies that have shown that S100B rises early in nonsurvivors, although the variability of levels among survivors and nonsurvivors is large (27, 29) . Previous studies have suggested that S100B may not have sufficient discriminatory power to be clinically useful (27, 29) .
With the exception of NGAL, the remaining novel biomarkers we investigated in his study were inconsistently or never associated with clinical outcome. HMGB is a ubiquitous nuclear protein involved in chromatin structure and also found in cytosol, where it is involved in sterile inflammation and autophagy (30) . This offers some face validity as a marker of the severity of the postarrest syndrome. Indeed, HMGB concentration was significantly higher in nonsurvivors than survivors at enrollment. However, the discriminatory power of enrollment HMGB level was lower than that of enrollment NGAL level, and in contrast to NGAL, subsequent HMGB levels did not predict outcome.
Leptin is a peptide expressed in neuronal tissue and extracranial adipose and has been evaluated as a prognostic marker after traumatic brain injury (31) but did not correlate with outcome in this cohort. ICAM-1 is a marker of endothelial dysfunction and pathologic central nervous system inflammatory states where it facilitates leukocyte adhesion and recruitment (32) . It also did not correlate with outcome in this cohort.
Our study has several important limitations. As a tertiarycare referral center, many of our patients are received in transfer from other facilities. As such, "enrollment" biomarker levels were not obtained immediately after CA. However, all "enrollment" biomarker levels were obtained within 6 hours of ROSC. For all subsequent time points, samples were obtained at fixed intervals from ROSC, but there was some variability in timing of the initial sample that reflects real-world clinical practice. In the case of NGAL, this variability does not alter our conclusions since the relationship with outcome was stable over time. Also, although we used several methods of model building to generate multivariable models, we could not adjust for several potentially important covariates, such as time intervals, from collapse to CPR and CPR to ROSC, which we have previously shown are unreliably documented in our care system (23) . It is possible that unmeasured confounders biased our findings, a limitation inherent to all observational studies.
Like many biomarker studies, we followed subjects' clinical outcomes to hospital discharge. Although this is an important marker of overall recovery, in patients with acquired brain injury, survival-to-hospital discharge is not necessarily a patient-centered outcome when compared with a favorable neurologic outcome. Future investigations may focus on subjects' neurologic recovery and long-term outcomes. As a single-center study, it is possible that some of our correlations we observed were influenced by our local standard of care. For example, the rise in many biomarkers after CA is influenced by therapeutic hypothermia. Although we systematically treated all comatose subjects in this study with therapeutic hypothermia, other local care practices may represent unmeasured confounders. Since comatose patients in this cohort were treated with hypothermia and also had a greater severity of illness, we are not able to differentiate the effects of hypothermia on biomarker levels from the effect of illness severity. The results of the recent Target Temperature Management trial, which support hypothermia to a goal of either 33 or 36°C, offer a future opportunity to disentangle this confounding in these most severely injured patients. Finally, although our local standard of care has not changed significantly since the recruitment period of this study, it is possible that recent changes in resuscitation and general critical care management and guidelines limit the generalizability of our results to other centers' current clinical practice. Contemporary, external validation of our findings by other groups is a necessary next step in exploring the utility of NGAL as a prognostic marker in this population.
CONCLUSIONS
In this exploratory study, it seems that serum NGAL levels are strongly predictive of survival-to-hospital discharge after CA. This relationship is stable over time, and addition of enrollment NGAL to clinical models improves overall model fit and discriminatory power. We believe that NGAL is an appealing candidate that merits further investigation in this patient population.
